BioSpace News Archive

Sobi North America announced a presentation from the REAL-HLH study – a chart review study which assessed real-world treatment patterns and outcomes in patients with hemophagocytic lymphohistiocytosis who were treated with Gamifant® – at the American College of Rheumatology Convergence 2022 Meeting taking place in Philadelphia from November 10-14, 2022.

Syndax Pharmaceuticals, Inc. announced that it will report its third quarter 2022 financial results and provide a business update on Thursday, November 3, after the close of the U.S. financial markets.

CytoSorbents Corporation will report third quarter 2022 operating and financial results after the market close on Thursday, November 3, 2022.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the ALTITUDE ® clinical trial evaluating RGX-314 using suprachoroidal delivery for the treatment of patients with diabetic retinopathy at the Retina Society 55th Annual Scientific Meeting taking place in Pasadena, CA , from November 2-5, 2022.

Seres Therapeutics, Inc . (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on November 2, 2022, at 8:30 a.m. ET to discuss third quarter 2022 results and provide a general business update.

Castle Biosciences, Inc. today announced new data from two studies demonstrating the potential of DecisionDx®-Melanoma and DecisionDx®-UM to accurately stratify risk of death from melanoma (cutaneous melanoma (CM) and uveal melanoma (UM), respectively) in a group of real-world, unselected and prospectively tested patients.

Deciphera Pharmaceuticals, Inc. today announced that it will report its third quarter 2022 financial results on Thursday, November 3, 2022.

Lumata Health announces $4MM in new venture funding to scale its impact throughout the United States.

Aurora Spine Corporation today announced positive interim results from a clinical study using the ZIP™ MIS Interspinous Fusion System.

Intellia Therapeutics, Inc. will present its third quarter 2022 financial results and operational highlights in a conference call on November 3, 2022, at 8 a.m. ET.